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Objective: Early-stage lung cancer is best treated by anatomic pulmonary
resection. Patients with lung cancer and severe emphysema are often
denied resection or are offered only limited, nonanatomic resections when
established pulmonary function criteria for lobectomy are not met. Re-
cently, with the introduction of the volume reduction operation, selected
patients with disabling emphysema have undergone excision of approxi-
mately 30% of the most destroyed lung tissue and have subsequently
demonstrated subjective and objective improvement in pulmonary function.
Using these principles, we elected to combine anatomic lobectomy with
volume reduction in a select group of patients with both emphysema and
lung cancer who would not otherwise be candidates for pulmonary resec-
tion. Methods: Five patients with severe emphysema and suspected or
proven lung cancers, who were poor candidates for anatomic lobectomy by
traditional criteria but were good candidates for volume reduction, under-
went lobectomy combined with volume reduction of one or more additional
lobes. Results: All five patients having lung volume reduction and anatomic
lobectomy for early-stage primary lung cancer did well postoperatively.
Furthermore, each patient has demonstrated subjective and objective
improvement in respiratory function on serial postoperative studies. Con-
clusions: Selected patients with disabling emphysema and suitable anatomy
for volume reduction, who have a lung cancer situated in destroyed lung
tissue, may benefit from combined lobectomy and volume reduction. The
introduction of the volume reduction operation has added a new factor in
the algorithm for the evaluation and treatment of lung cancer in selected
patients with advanced emphysema. (J Thorac Cardiovasc Surg 1998;115:
681-8)
Early-stage non-small-cell lung cancer is best treatedby surgical resection. Ideally, the resection should
consist of either lobectomy or pneumonectomy. Lim-
ited resection with wedge excision or segmentectomy
has been associated with a significantly increased risk
of local recurrence and a reduction in both overall and
disease-free survival.1 Occasionally though, associated
emphysema in patients with lung cancer so compro-
mises pulmonary function as to preclude resection.
For such patients alternative treatment strategies in-
cluding radiation therapy, with or without chemother-
apy, have yielded comparatively poor results.2, 3 Fur-
thermore, high-dose radiation may lead to as much
reduction in pulmonary function as a surgical resec-
tion. Thus limited pulmonary function in patients
represents as much a management problem for the
radiation oncologist as for the surgeon.4 This dilemma
is further compounded for surgeons by the lack of a
precisely definable point at which the risk-to-benefit
ratio for resection becomes unfavorable, particularly in
light of improvements in the anesthetic, surgical, and
postoperative treatment of patients with advanced
emphysema.
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We have previously reported the beneficial early
and intermediate-term results of lung volume reduc-
tion (LVR) in 150 selected patients with advanced
emphysema.5, 6 In 10% of these patients a complete,
anatomic lobectomy was included in the bilateral
procedure because the entire lobe was destroyed by
emphysema and the anatomic findings at operation
were favorable for a lobectomy. Interestingly, patho-
logic examination of resected lung tissue in 2 of the
150 patients revealed a focus of cancer not detected
preoperatively. Subsequently, five patients were
seen with suspected or proven lung cancer and
severe emphysema anatomically amenable to LVR.
In each patient the respiratory compromise from
emphysema was so severe that under previous se-
lection criteria none of them would have been
considered suitable candidates for a major pulmo-
nary resection. Furthermore, in each patient the
lung cancer was situated such that wedge excision
would be difficult or impossible. However, given the
demonstrated benefits of LVR in patients with a
suitable anatomic situation, and the lack of satisfac-
tory alternative treatment in these select patients
with lung cancer, we chose to perform a cancer
resection with anatomic lobectomy in conjunction
with LVR. The purpose of this report is to describe
these cases and the early postoperative results.
Methods
Between October 1994 and October 1996, 608 patients
with severe emphysema were evaluated at Barnes Hospi-
tal as potential candidates for LVR operations. Among
these 608 patients, 142 were determined to be acceptable
candidates and went on to have LVR operations. Among
the 142 patients accepted for operation were three pa-
tients (2.1%) in whom chest x-ray films showed a pulmo-
nary nodule suspicious for carcinoma. Another two pa-
tients with severe emphysema were referred for
evaluation of newly diagnosed lung cancers. These five
patients (patients a through e) form the basis for this
report.
The mean age of the five patients was 62 years (range 53
to 70 years), and three were men. None of the patients
had symptoms from the cancer, but all had symptoms of
advanced emphysema. Two patients had dyspnea at rest
(patients c and d) and required continuous supplemental
oxygen. One patient (patient d) was receiving 30 mg/day
of prednisone when first evaluated but was weaned to 5
mg/day before operation. A preoperative diagnosis of
cancer was made in four patients (all except patient a).
Evaluation in each patient included inspiratory and expi-
ratory posteroanterior and lateral chest x-ray films, chest
computed tomographic scans including views of the liver
and adrenal glands, and a ventilation/perfusion scan. A
representative chest x-ray film and a ventilation/perfusion
scan from one patient (patient a) are shown in Fig. 1.
Candidates for combined lobectomy and volume reduc-
tion had to have radiographic and scintigraphic evidence
of severe emphysema in a heterogeneous distribution.
Furthermore, the pulmonary nodule had to be located in
Fig. 1. A, Posteroanterior chest x-ray film of patient a showing characteristics of severe emphysema
including bilateral pulmonary hyperinflation and flattened diaphragms. The right upper lobe nodule is
faintly visible. B, Posterior view of the ventilation portion of a ventilation-perfusion scan from the same
patient. The left lung has greater overall ventilation, and there is bilateral upper lobe destruction,
particularly on the right.
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one of the more destroyed lobes. Evaluation of each
patient also included pulmonary function tests (PFTs), an
arterial blood gas, and a 6-minute walk test (Table I).
Systemic staging consisted of a brain computed tomogram
and radionucleotide bone scan in each patient. A nonin-
vasive cardiac evaluation was done before the operation
as a standard procedure. One patient (patient e) was
found to have coronary artery disease and ultimately
required angioplasty before undergoing pulmonary resec-
tion. In another patient (patient c), a prior myocardial
infarction resulted in a reduced left ventricular ejection
fraction (26%), but no areas of active ischemia were
identified. No other nonpulmonary organ dysfunction was
identified in these patients.
Before resection four of the five patients underwent 6 to
8 weeks of supervised pulmonary rehabilitation. One
patient (patient b), in whom the lung cancer was discov-
ered on a chest x-ray film done in an emergency depart-
ment after a biking accident, was in good physical condi-
tion and did not undergo preoperative rehabilitation. In
another patient (patient d), the pulmonary nodule became
apparent after rehabilitation, before the planned LVR
operation.
At operation, each patient underwent bronchoscopy,
and four of the five patients had mediastinoscopy. One
patient (patient a) had a small, undiagnosed right upper
lobe lung nodule with no computed tomographic evidence
of mediastinal adenopathy, and she did not undergo
mediastinoscopy. A median sternotomy was used in four
of the five patients. One patient (patient d) had previously
undergone bleb excision and pleurectomy on the left side
because of recurrent spontaneous pneumothorax, and he
underwent bilateral staged thoracotomies. Pleural tents
were used to eliminate residual intrathoracic space after
resection in two of the five patients. The operative proce-
dure and pathologic stage of the resected tumor for each
patient are shown in Table II.
Postoperative pain management for each patient con-
sisted of a thoracic epidural catheter and a combination of
narcotic and local anesthetic. Each patient was extubated
in the operating room and taken to the thoracic observa-
tion (step-down) unit after a short stay in the recovery
room. Chest physiotherapy was initiated on the day of the
operation and continued throughout the hospital stay.
Ambulation and pulmonary rehabilitation began on the
first postoperative day. Postoperative bedside bronchos-
copy and a minitracheotomy procedure were used when
necessary. Patients were discharged from the hospital
after removal of the last chest tube (range 7 to 24 days
after the operation, mean 12.8 days).
Results
Preoperative structured pulmonary rehabilitation
was used in four of the five patients. There was no
significant difference in any PFT parameter after
rehabilitation in these four patients. However, the
two most deconditioned patients (patients c and d)
Table I. Results of pulmonary function, arterial blood gas, and 6-minute walk tests for the five patients at the
time they were accepted for surgical treatment
Patient
a b c d e
FVC (L) 1.98 (70)* 3.12 (71) 2.00 (74) 3.13 (76) 2.80 (74)
FEV1 (L) 0.64 (28) 1.14 (33) 0.67 (33) 0.85 (24) 0.90 (30)
FEV25-75 (L/sec) 0.20 (9) 0.40 (12) 0.23 (10) 0.21 (5) 0.15 (5)
TLC (L) 6.86 (138) 11.6 (160) 6.21 (133) 9.26 (129) 9.26 (145)
RV (L) 4.88 (232) 8.43 (340) 4.15 (221) 6.06 (287) 6.40 (308)
DLCOunc% 44 37 43 23 44
PaO2 (mm Hg) (RA)† 64 59 72 38 77
PaCO2 (mm Hg) 33.7 37.5 36 54 42
6-Min walk (feet) 1100 NA 600 40 1800
FVC, Forced vital capacity; TLC, total lung capacity; RV, residual volume; DLCOunc%, uncorrected diffusing capacity as a percentage of predicted; PaO2,
arterial oxygen tension; PaCO2, arterial carbon dioxide tension.
*The number in parenthesis is the percent of predicted for that patient.
†RA refers to inspired oxygen concentration equal to room air.
Table II. Location of the tumor, operative procedure performed, pathologic features including stage, and
postoperative discharge day for each of the five patients
Patient Tumor location Operative procedure Pathology Postop. discharge day
a RUL RU lobectomy with LUL reduction Adenocarcinoma, stage I 7
b RML RM lobectomy with bilateral UL reduction Adenocarcinoma, stage I 13
c RML RM lobectomy with RUL reduction Adenocarcinoma, stage I 24
d LUL Staged RU lobectomy, LU lobectomy Adenocarcinoma, stage I 9/12 (first/second operation)
e LUL LU lobectomy with RUL reduction Squamous cell, stage II 12
RUL, Right upper lobe; LUL, left upper lobe; RML, right middle lobe; UL, upper lobe.
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demonstrated substantial improvement in 6-minute
walk distance after rehabilitation as shown in Fig. 2.
These two patients continued to show improvement
in 6-minute walk distance in the postoperative pe-
riod. Interestingly, the two patients who were better
conditioned at evaluation (patients a and c) demon-
strated no improvement with rehabilitation and
covered less distance in the early postoperative
period than they had immediately before the oper-
ation. With longer follow-up, however, the 6-minute
Fig. 2. Distance walked in 6 minutes in each of the four patients who underwent preoperative pulmonary
rehabilitation. The greatest gains were demonstrated in the patients most deconditioned at the time of
evaluation (patients c and d). The best-conditioned patients at the time of evaluation (patients a and e) did
not improve with preoperative structured pulmonary rehabilitation and showed early postoperative decline
in 6-minute walk distance.
Fig. 3. FEV1 values improved in each patient after lobectomy and volume reduction when compared with
the postrehabilitation, preoperative value. The improvements have persisted for 2 years in one patient and
for 1 year in two patients. Peak postoperative improvement seems to occur during the first 6 months and
is followed by a slow decline toward the preoperative value (see discussion). Importantly, note that the
postoperative FEV1 value was not decreased after lobectomy and volume reduction in any of the five
selected patients with advanced emphysema and lung cancer.
The Journal of Thoracic and
Cardiovascular Surgery
March 1998
6 8 4 DeMeester et al.
walk distance has steadily improved in the one
patient with a 2-year follow-up after resection.
Despite the fluctuations in postoperative 6-minute
walk distance, each patient has had significant subjec-
tive and objective improvement in pulmonary func-
tion. Measurable improvements in the first-second
forced expiratory volume (FEV1), total lung capacity,
and residual volume were seen in all five patients as
shown in Figs. 3 and 4. These improvements have
persisted for 2 years after the operation in one patient
(patient a), albeit with a slow, steady return toward the
preoperative values. Maximal postoperative improve-
ment in FEV1 averaged 43% in the five patients, with
a range from 27% to 51%. Importantly, in no patient
did the FEV1 decrease after resection. In addition to
the improvement in pulmonary function, each patient
has benefited from optimal treatment for the lung
cancer. In four of the five patients the lung cancer was
found to be stage I and they required no further
therapy. The one patient with a stage II cancer (patient
e) received postoperative adjuvant radiation therapy.
During a mean follow-up of 19 months there has been
no evidence of new or recurrent cancer in any of the
patients.
There was no mortality; however, three of the five
patients had complications. One patient’s hospital-
ization (patient b) was prolonged as a consequence
of bronchitis and retained airway secretions neces-
sitating bedside bronchoscopy. A pneumothorax de-
veloped in one patient (patient c) after chest tube
removal and in combination with retained airway
secretions produced respiratory distress necessitat-
ing intubation and mechanical ventilation. Bron-
choscopy and chest tube placement were performed,
and the patient was successfully extubated less than
24 hours after intubation. However, a prolonged air
leak from the new chest tube delayed the patient’s
discharge from the hospital. Both of the patients
with pleural tents (patients b and e) had postoper-
ative bleeding into the extrapleural space created by
the pleural tent. Blood transfusion and placement of
a chest tube into the intrathoracic, extrapleural
space were required in each patient. In both patients
the chest tube adequately decompressed the ex-
trapleural space, and no further therapy was re-
quired.
Discussion
Cigarette smokers are at increased risk for both
emphysema and lung cancer.7, 8 In a review from the
University of Pittsburgh, 4.8% of patients evaluated
for LVR operations were found to have an unsus-
pected lung lesion. Of these lesions, 60% proved to
be primary lung cancers.9 Although surgical resec-
tion with an anatomic lobectomy or pneumonec-
tomy has been demonstrated to be the optimal
treatment for patients with early-stage lung cancer,
the presence of significant emphysema has elimi-
Fig. 4. Both total lung capacity (TLC, shown in bold lines) and residual volume (RV, shown in light lines)
decreased after lobectomy and volume reduction in selected patients with advanced emphysema and lung
cancer.
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nated many patients from consideration for major
pulmonary resection.
A number of studies have examined the relation-
ship of preoperative PFT findings and operative
outcome in an attempt to predict perioperative risk
for a patient requiring pulmonary resection and to
define criteria for inoperability. In 1971 Boushy and
associates10 reported that of all the PFT values,
FEV1 was the most helpful in selecting patients at
high risk for postoperative mortality. Miller, Gross-
man, and Hatcher11 in 1981 and Miller12 in 1993
published findings from a series of 1831 pulmonary
resections, including 785 lobectomies and 161 pneu-
monectomies, which were done with an overall
operative mortality rate of 0.65%. In this series, the
minimum criteria for lobectomy were a maximal
voluntary ventilation greater than 40% of predicted,
an FEV1 value greater than 1 L, and an FEV25-75
value of greater than 0.6 L. Ferguson and col-
leagues,13 on the other hand, analyzed PFT data
from 237 patients who underwent pulmonary resec-
tion and determined that the most important pre-
dictor of death and pulmonary complications was
the corrected diffusing capacity as a percentage of
predicted. They recommended that patients in
whom this value was less than 60% be excluded from
consideration for major pulmonary resection.
In an effort to further define the operative risk in
patients with marginal PFT findings, Olsen and
Block,14 Kristersson,15 Ali,16 Wernly,17 and their
associates have reported on methods to quantify
differential lung function on the basis of xenon 133
ventilation radiospirometry with or without techne-
tium 99 perfusion scanning. In the series by Wernly
and coworkers,17 patients with a predicted post-
resection FEV1 value of less than 1 L were consid-
ered unfit for resection. Others have suggested that
the loss of pulmonary vascular compliance or an
impaired maximal oxygen consumption during exer-
cise will help define patients at high risk for resec-
tion.
Despite the multitude of methods to assess peri-
operative risk for resection, the fact remains that no
single test, number, or percentage has been demon-
strated to reliably separate patients who will tolerate
resection from those who will not. Rather, most
thoracic surgeons rely on several of these tests, in
addition to the overall physical state of the patient,
to select operative candidates. With the develop-
ment of LVR operations, however, patients with
advanced emphysema who do not meet traditional
PFT and clinical criteria for pulmonary resection
have undergone resection of 20% to 40% of the
volume of each lung and have shown remarkable
postoperative improvement in both symptoms and
measured pulmonary function.18 Postulated mecha-
nisms include an improvement in elastic recoil of the
lung; reduced airway resistance; an improvement in
diaphragmatic function, chest wall mechanics, and
respiratory muscle efficiency; and an overall reduc-
tion in ventilation/perfusion mismatch.18-20
Having established a successful volume reduction
program, and having gained experience with the
perioperative treatment of patients with advanced
emphysema, it seemed logical to extend the benefits
of the volume reduction concept to a select group of
patients with the combination of early-stage lung
cancer and severe emphysema. Patients whose dis-
ease might otherwise be considered inoperable
could potentially undergo an optimal cancer opera-
tion with anatomic lobectomy and simultaneously
achieve an overall improvement in respiratory sta-
tus. This is precisely what has occurred in this early
series of patients, each of whom had PFT values that
in one or more categories fell well below the tradi-
tionally accepted minimal criteria for lobectomy.
Consistent with reports on patients who have under-
gone volume reduction operation alone, each of
these patients had postoperative improvement in
the PFT findings, with an increase in FEV1 and a
decrease in the total lung capacity and residual
volume. These objective improvements in measured
pulmonary function correlated with improvement in
each patients’ symptoms of dyspnea and with an
improvement in the 6-minute walk distance in four
of the five patients.
It is important to recognize that in these selected
patients, as a consequence of the heterogeneous
distribution of the emphysema, anatomic lobectomy
was accomplished without any patient having a
decrease in FEV1 values after resection. Further-
more, the PFT improvements have persisted in the
postoperative period, although a slow return toward
the preoperative values is apparent in the one
patient with 2-year follow-up. This steady decline
likely represents the natural history of severe em-
physema, with gradual deterioration of the remain-
ing emphysematous lung tissue. This finding rein-
forces the concept that volume reduction operations
may “set the clock back” for patients with advanced
emphysema but do not cure them of the disease.
As with any volume reduction operation, we
believe that a combined cancer and volume reduc-
tion operation should be offered only to a very select
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group of patients. Specifically, ideal candidates for a
combined operation would have symptomatic em-
physema with hyperinflated lungs and target areas
of severe destruction, with the cancer located in a
target lobe. Two of our patients were not ideal in
that the cancer was in the middle lobe, whereas the
most destroyed lung was in the upper lobes. How-
ever, middle lobectomy in combination with upper
lobe volume reduction was well tolerated in each
patient despite the loss of some functioning middle
lobe lung parenchyma. In some patients a lobectomy
alone may suffice both for the cancer operation and
the volume reduction effect. Indeed, anecdotal re-
ports have circulated for years among thoracic sur-
geons about patients with severe emphysema who
believed they were able to breathe better after a
lobectomy, usually of an upper lobe, done because
of lung cancer. Patients with significant emphysema
and cancer located in the areas of best-preserved
lung, however, would not be candidates for a lobec-
tomy. In this circumstance one might consider a
wedge or segmental excision of the cancer concom-
itant with LVR. Although this approach leads to an
increased risk of local recurrence, in suitable candi-
dates it likely would leave the patient with a better
respiratory status and a better chance of cure than
would primary radiation therapy. Radiation therapy,
in nearly all circumstances, will leave the patient
with worse pulmonary function than they had at the
onset of treatment. Surgical resection, in appropri-
ate candidates, not only offers the best chance for
cure but is also the only treatment modality with the
potential to improve the patients’ respiratory status
after therapy. As such, operation should be consid-
ered in patients with an appropriate anatomic situ-
ation regardless of the degree of impairment in
measured PFTs. In this series, patients were care-
fully screened for the presence of comorbid condi-
tions. Likely, the presence of nonpulmonary organ
dysfunction would greatly increase the operative
risks in these patients and should be factored into
the decision on how to treat the lung cancer.
A number of issues remain unresolved. It has been
our policy not to consider LVR in any patient who has
smoked cigarettes within the previous 6 months. Fur-
thermore, we insist on a period of preoperative pul-
monary rehabilitation, usually for 8 weeks, with the
goal of maximizing exercise endurance and capacity.
To what extent these requirements should be altered
in patients with coexisting lung cancer remains unde-
termined. Review of our experience with structured
pulmonary rehabilitation in patients undergoing LVR
has shown that with preoperative rehabilitation pa-
tients improve their 6-minute walk distance an average
of 30% to 40% over the distance at the time of
evaluation. In this group of five patients, four had
preoperative rehabilitation, and two of these patients
demonstrated improvement in 6-minute walk distance.
One patient was found to be severely deconditioned at
evaluation and with 8 weeks of rehabilitation increased
his 6-minute walk distance by 2725% (from 40 feet to
1090 feet). Clearly, patients in the worst cardiorespi-
ratory condition at the time of evaluation stand to gain
the most with preoperative rehabilitation, whereas the
gains in those in better condition initially are likely to
be marginal. Indeed, one of the five patients in this
report was judged at evaluation to be fit and did well
without any preoperative rehabilitation. Furthermore,
the two patients who had 6-minute walk distances
greater than 1000 feet at evaluation did not show any
improvement with structured pulmonary rehabilita-
tion. Thus delay in resection for rehabilitation is
probably only justified in the most deconditioned
patients, and perhaps the 6-minute walk test might
prove to be a helpful discriminator to determine who
might benefit most from preoperative structured pul-
monary rehabilitation. Currently, however, a minimum
of several weeks of smoking cessation and exercise
rehabilitation would, in our opinion, seem essential in
many of these patients.
In summary, we believe that the introduction of
volume reduction operations has added a new arm
in the algorithm for the evaluation and treatment of
lung cancer in patients with advanced emphysema.
In this report we have demonstrated that within the
group of patients with both emphysema and lung
cancer there exists a subset of patients whose dis-
ease is anatomically suitable for a combined lobec-
tomy and volume reduction. This combination not
only allows an optimal cancer resection in patients
who might otherwise be considered inoperable, but
also in appropriately selected patients results in
improved postoperative subjective and objective
pulmonary function. Thus patients with lung cancer
and poor PFT findings should not automatically be
labeled as unfit for resection. Rather, given the
propensity for both emphysema and lung cancer to
occur in patients with a significant smoking history,
it is likely that a combined approach could be
applicable to a significant number of patients. Un-
doubtedly, further experience with LVR operations,
both alone and in combination with a cancer oper-
ation, will help refine the indications, contraindica-
tions, and limitations of such an approach.
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